Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
about
Possible application of circulating free tumor DNA in non-small cell lung cancer patients.GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature.About molecular profile of lung cancer in Tunisian patients.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Tumour heterogeneity and resistance to cancer therapies.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Tumor biomarker testing in non-small-cell lung cancer: A decade of change.Analytic inquiry: Molecular testing in lung cancer.Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.A richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapyPrecision oncology: separating the wheat from the chaffGenomics of adult and pediatric solid tumors
P2860
Q47158413-2F1F3EBE-E7BD-474C-A1DC-D658B7C088F1Q47160378-F25FA98B-1172-41DE-BFC8-2EEDC2E0D208Q47198922-A5C88F92-6A39-4577-B6DF-6D181521C424Q49188022-5851787D-0A7B-47E5-BE5A-CC542A992D73Q50027697-A759C3DB-8D91-4F7E-87A9-4BEEFD3248F4Q50112440-2C0ABBB2-1BC6-407E-A76B-0E931A0F3192Q50115014-A83D8EE3-F127-4A9F-B590-309025100394Q50139910-3E71F5C7-AF2E-4849-B2A7-D8C18E979046Q50947169-A5B8D410-6469-415F-A84A-27D6750DF8E9Q52587597-EBC7439D-3983-4347-970A-1351C935897AQ53078885-47AE84F8-EECB-4C88-BABB-80024130DB61Q55025386-29871D84-24AE-4473-99B8-6C2C5C4BF509Q55062993-429F2A82-3304-4561-86E9-30F41B30AC43Q55515297-4E813F6F-2A2A-4CE2-9C9F-6E026B6DE5ADQ57167684-87CBCEC8-DD74-4EA8-83E2-4E7655E61B14Q58698377-7AC779B8-1E8A-4643-9617-9CB0A85845E0Q58804574-71675B72-B669-40BB-884E-FD2678F25F38
P2860
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Prospective Comprehensive Mole ...... proved and Emerging Therapies.
@en
type
label
Prospective Comprehensive Mole ...... proved and Emerging Therapies.
@en
prefLabel
Prospective Comprehensive Mole ...... proved and Emerging Therapies.
@en
P2093
P2860
P50
P1433
P1476
Prospective Comprehensive Mole ...... pproved and Emerging Therapies
@en
P2093
Ahmet Zehir
Alexander Drilon
Aphrothiti J Hanrahan
Barry S Taylor
David B Solit
David Barron
David M Hyman
Debyani Chakravarty
P2860
P304
P356
10.1158/2159-8290.CD-16-1337
P577
2017-03-23T00:00:00Z